Jason Gerberry analyst BAML

Currently out of the existing stock ratings of Jason Gerberry, 180 are a BUY (65.93%), 63 are a HOLD (23.08%), 30 are a SELL (10.99%).

Jason Gerberry

Work Performance Price Targets & Ratings Chart

Analyst Jason Gerberry, currently employed at BAML, carries an average stock price target met ratio of 60.93% that have a potential upside of 27.02% achieved within 279 days.

Jason Gerberry’s has documented 569 price targets and ratings displayed on 59 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on LLY, Eli Lilly and Company at 15-Dec-2025.

Wall Street Analyst Jason Gerberry

Analyst best performing recommendations are on ARWR (ARROWHEAD PHARMACEUTICALS).
The best stock recommendation documented was for ARWR (ARROWHEAD PHARMACEUTICALS) at 12/1/2025. The price target of $62 was fulfilled within 2 days with a profit of $9.3 (17.65%) receiving and performance score of 88.24.

Average potential price target upside

ABBV AbbVie AGN Allergan plc ALKS Alkermes Plc BHC Bausch Health Companies BLUE Bluebird bio BYSI BeyondSpring ENDP Endo International PLC FGEN FibroGen GLPG Galapagos NV ADR HZNP Horizon Pharma PLC IONS Ionis Pharmaceuticals JAZZ Jazz Pharmaceuticals PLC LLY Eli Lilly and Company MNK Mallinckrodt plc MRK Merck mpany MRTX Mirati Ther MYL Viatris PCVX Vaxcyte  TARS Tarsus Pharmaceuticals  TEVA Teva Pharma Industries Ltd ADR ALLO Allogene Therapeutics BMY Bristol-Myers Squibb Company HRTX Heron Therapeuti MNTA Momenta Pharmaceuticals PFE Pfizer AKRX Akorn ARNA Arena Pharmaceuticals AVDL Avadel Pharmaceuticals PLC CORI Corium International KRTX Karuna Therapeutics PRGO Perrigo Company PLC DICE Dice Molecules Holdings LLC FWP Forward Pharma A S VTRS Viatris OGN Organon ACLX Arcellx AERI Aerie Pharmaceuticals AMTI Applied Molecular Transport  CARA Cara Therapeutic LYRA Lyra Therapeutics  CHRS Coherus BioSciences RLAY Relay Therapeutics  XENE Xenon Pharmaceuticals AXSM Axsome Therapeutics ARWR Arrowhead Pharmaceuticals HRMY Harmony Biosciences Holdings ITCI Intracellular Th AMPH Amphastar P CPRX Catalyst Pharmaceuticals EXEL Exelixis IMVT Immunovant  OCS Oculis Holding AG Ordinary shares PROK ProKidney Corp. BHVN Biohaven Pharmaceutical Holding Co Ltd KALV Kalvista Pharmaceuticals NBRV Nabriva Therapeutics AG SESN Sesen Bio VRCA Verrica Pharmaceuticals ASRT Assertio Therapeutics

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

Since 24-Jan-2022

$269

$40.51 (17.73%)

$250

25 days ago
(12-Dec-2025)

17/19 (89.47%)

$45.02 (20.10%)

467

Buy

Since 17-May-2024

$280

$51.51 (22.54%)

$200

1 months 24 days ago
(13-Nov-2025)

5/6 (83.33%)

$46.77 (20.05%)

236

Buy

Since 31-Oct-2023

$237

$8.51 (3.72%)

$188

2 months 2 days ago
(04-Nov-2025)

2/3 (66.67%)

$18.96 (8.70%)

109

Hold

Since 14-May-2025

$235

$6.51 (2.85%)

$251

2 months 3 days ago
(03-Nov-2025)

16/17 (94.12%)

$16.96 (7.78%)

282

Buy

Since 16-Oct-2020

$260

$31.51 (13.79%)

$235

2 months 3 days ago
(03-Nov-2025)

14/15 (93.33%)

$41.96 (19.24%)

483

Show more analysts

Please expand the browser size to see the chart

Which stock is Jason Gerberry is most bullish on?

Potential upside of $187.64 has been obtained for LLY (ELI LILLY AND COMPANY)

Which stock is Jason Gerberry is most reserved on?

Potential downside of -$5.79 has been obtained for ARWR (ARROWHEAD PHARMACEUTICALS)

What Year was the first public recommendation made by Jason Gerberry?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?